Market Research Logo

Antifungal Drugs: Technologies and Global Markets

Antifungal Drugs: Technologies and Global Markets

The global market for antifungal drugs was valued at $13.1 billion in 2016. The market should reach $16.1 billion by 2021, growing at a compound annual growth rate (CAGR) of 4.2% from 2016 to 2021.

Report Includes
An overview of the global market for antifungal drugs.
Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
Identification of new antifungal research, development, and drug applications.
Heavy focus on therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources.
Information on over the counter (OTC) vs. prescription products.
Profiles of major players in the industry.


Report Scope
The aim of this report is to initially conduct a review of the antifungal drugs currently available, the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies, and their intended clinical applications.

The key objective was also to conduct and provide an analysis of the market value, growth rates, market shares, market development as well as examining the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

A detailed analysis of the revenues and forecasts for the global antifungal drugs market with a further more detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and finally by selected country.

A detailed analysis of the global market share together with a further more detailed analysis of the market share by geographic regions and finally by selected country.

In addition this analysis provides a:
Detailed review of the current products, their indications and availability for all the market segments identified.
Profile of the individual markets sub-segments within the major market segments analyzed and the distinguishing features of each of the market sub-segments.
Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
Brief description of the historical development for each of the major market segments.
Profile of the leading suppliers of antifungal drugs together with related information about specific products.

The study will allow the reader to:
Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the antifungal drug market.
Investigate the current market dynamics that are driving change in the antifungal drug market.
Assess future growth opportunities in the antifungal drug market.
Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
Utilize the report to help realize an individual company’s position in the market place and to provide insight into the future of the market and the opportunities that exist.

CHAPTER 1 INTRODUCTION
INTRODUCTION TO THE REPORT
REASONS FOR DOING THIS STUDY
SCOPE
METHODOLOGY
PRIMARY DATA AND INFORMATION GATHERING
SECONDARY DATA AND INFORMATION GATHERING
MARKET SHARE ANALYSIS AND MARKET FORECAST PREDICTION
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
MARKET SEGMENTATION
GLOBAL MARKET REVENUE ANALYSIS BY MARKET SEGMENT
SUMMARY TABLE GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE A GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
SUMMARY FIGURE B GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
CHAPTER 3 INTRODUCTION TO THE GLOBAL ANTIFUNGAL DRUG MARKET
SCOPE OF APPLICATIONS: HUMAN HEALTHCARE
PRIMARY FUNGAL INFECTIONS
TABLE 1 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
OPPORTUNISTIC FUNGAL INFECTIONS
HUMAN FUNGAL INFECTIONS
SELECTION OF STATISTICAL DATA ON FUNGAL INFECTIONS
FIGURE 1 GLOBAL BURDEN OF HIV-RELATED CRYPTOCOCCAL MENINGITIS
(ESTIMATED YEARLY CASES)
FUNGAL INFECTION OF THE NAILS
TABLE 2 STATISTICS OF THE 10 MOST SIGNIFICANT INVASIVE FUNGAL
INFECTIONS
RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS
TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS
CANDIDIASIS
Some Basic Facts about Candida Infections
Cutaneous Candidiasis
Chronic Mucocutaneous Candidiasis
GI Tract Candidiasis
Respiratory Tract Candidiasis
Genitourinary Tract Candidiasis
Hepatosplenic Candidiasis
Systemic Candidiasis
CANDIDEMIA
Disseminated Candidiasis
ASPERGILLOSIS
BLASTOMYCOSIS
COCCIDIOIDOMYCOSIS
CRYPTOCOCCOSIS
DERMATOPHYTOSIS
HISTOPLASMOSIS
ONYCHOMYCOSIS
PARACOCCIDIOIDOMYCOSIS
PSEUDALLESCHERIASIS
SPOROTRICHOSIS
ZYGOMYCOSIS
TABLE 4 EPIDEMIOLOGY OF COMMON FUNGAL DISEASES
RARE FUNGAL INFECTIONS AND DISORDERS
TABLE 5 MORPHOLOGIC FEATURES OF FUNGI AND PSEUDOFUNGI
INFECTIONS OF UNUSUAL OR UNCERTAIN ETIOLOGY
LITERATURE REVIEW
CHAPTER 4 COMMON ENVIRONMENTAL FUNGI
MOLDS AND THE HUMAN ISSUES ASSOCIATED WITH THEM
WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM
HEALTH RISKS DUE TO ENVIRONMENT FUNGI AND MOLD
TABLE 6 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS
TABLE 7 RISK FACTORS ASSOCIATED WITH ENVIRONMENTAL FUNGI AND MOLDS
TABLE 8 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS
ENVIRONMENTAL MOLDS
ALTERNARIA
Literature Review
ASPERGILLUS
Literature Review
CLADOSPORIUM
Literature Review
PENICILLIUM
Literature Review
EUROTIUM
Literature Review
RHIZOPUS
Literature Review
MUCOR
Literature Review
GEOTRICHUM
Literature Review
FUSARIUM
Literature Review
STACHYBOTRYS
Literature Review
WALLEMIA
Literature Review
TRICHOTHECIUM
Literature Review
SCOPULARIOPSIS BREVICAULIS
Literature Review
SCYTALIDIUM DIMIDIATUM
Literature Review
TRICHODERMA
Literature Review
PAECILOMYCES VARIOTII
Literature Review
CHAPTER 5 ANTIFUNGAL AGENTS
ANTIFUNGAL AGENTS
TABLE 9 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
GLOBAL MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
TABLE 10 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
FIGURE 2 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, 2015 - 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
TABLE 11 GLOBAL MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
CLASSIFICATION OF ANTI FUNGAL AGENTS
Classification of Antifungal Drugs
TIMELINE OF ANTIFUNGAL DRUG DEVELOPMENT
FIGURE 3 TIMELINE OF ANTIFUNGAL DRUG DEVELOPMENT
SYSTEMIC ANTIFUNGAL DRUGS
POLYENES ANTIBIOTICS
TABLE 12 PATENTS FOR AMPHOTERICIN B AND ESTIMATED EXPIRY
DATES
AZOLES
THE TRIAZOLE ANTIFUNGAL DRUGS
Fluconazole
TABLE 13 APPROVED FLUCONAZOLE PRESCRIPTION PRODUCTS
Itraconazole
TABLE 14 PATENTS FOR ITRACONAZOLE AND ESTIMATED EXPIRY
DATES
Voriconazole
TABLE 15 PATENTS FOR VORICONAZOLE AND ESTIMATED EXPIRY
DATES
TABLE 16 APPROVED VORICONAZOLE PRESCRIPTION PRODUCTS
Posaconazole
TABLE 17 PATENTS FOR POSACONAZOLE AND ESTIMATED EXPIRY
DATES
THE IMIDAZOLES ANTIFUNGAL DRUGS
Ketoconazole
TABLE 18 PATENTS FOR KETOCONAZOLE AND ESTIMATED EXPIRY
DATES
Miconazole
TABLE 19 APPROVED MICONAZOLE OTC PRODUCTS
Clotrimazole
TABLE 20 INTERNATIONAL BRAND NAMES FOR CLOTRIMAZOLE
TABLE 21 APPROVED GENERIC PRESCRIPTION VERIONS OF CLOTRIMAZOLE
ECHINOCANDINS
CASPOFUNGIN
TABLE 22 PATENTS FOR CASPOFUNGIN AND ESTIMATED EXPIRY DATES
Micafungin
TABLE 23 PATENTS FOR MICAFUNGIN AND ESTIMATED EXPIRY DATES
Anidulafungin
TABLE 24 PATENTS FOR ANIDULAFUNGIN AND ESTIMATED EXPIRY
DATES
ANTIMETABOLITE: FLUCYTOSINE (5-FC)
OTHER SYSTEMIC ANTIFUNGAL AGENTS
CHITIN SYNTHESIS INHIBITORS
MANNOPROTEIN SYNTHESIS INHIBITORS
SPHINGOLIPID SYNTHESIS INHIBITORS
TOPICAL ANTIFUNGAL DRUGS
TOPICAL POLYENE ANTIBIOTICS
Nystatin
Hamycin
Natamycin (pimaricin)
Filipin
AZOLES-IMIDAZOLE
Econazole
Butoconazole
Oxiconazole
Sulconazole
Fenticonazole
Isoconazole
Bifonazole (Mycospor)
Tioconazole
Terconazole
OTHERS
CHAPTER 6 SUMMARY: GLOBAL MARKET FOR ANTIFUNGAL DRUGS
INTRODUCTION
MARKET REVENUE ANALYSIS
GLOBAL MARKET REVENUE ANALYSIS
TABLE 25 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 26 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 4 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
GLOBAL MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
FIGURE 5 GLOBAL MARKET SHARE FOR ANTIFUNGAL DRUGS, BY REGION, 2015 (%)
NORTH AMERICA: MARKET REVENUE ANALYSIS
TABLE 27 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 28 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 6 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
EUROPE: MARKET REVENUE ANALYSIS
TABLE 29 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 30 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 7 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
ASIA-PACIFIC: MARKET REVENUE ANALYSIS
TABLE 31 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 32 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 8 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
LATIN AMERICA: MARKET REVENUE ANALYSIS
TABLE 33 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 34 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 9 LATIN AMERICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS
TABLE 35 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 36 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 10 MIDDLE EAST/AFRICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
CHAPTER 7 NORTH AMERICAN MARKET FOR ANTIFUNGAL DRUGS
REGULATORY AND LEGISLATIVE REQUIREMENTS
UNITED STATES
Investigational New Drug (IND) Application
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
OVER-THE-COUNTER (OTC) ANTIFUNGAL DRUG PRODUCTS
New Drug Application (NDA) Process
OTC Drug Monograph System
CANADA
MARKET DYNAMICS
MARKET DRIVERS
Emerging Pipeline of New and Innovative Antifungal Drugs
Spread of Fungal Disease Caused by Widespread Use of Broad
Spectrum Antibiotics
Increasing Number of People with Weakened Immune Systems
The Food and Drug Administration Safety and Innovation Act (FDASIA)
MARKET RESTRAINTS
Increasing Resistance of Fungi to Antifungal Drugs
Increased Popularity of Traditional Medicines and Alternative
Treatments to Control Fungus
Allergic Reaction to some Types of Antifungal Drugs such as Azoles
which Cause Anaphylaxis
Impact of the Patient Protection and the Affordable Care Act of 2010 on
the U.S. Antifungal Drug Market
Growth and Development of the Generic Antifungal Drugs Market
Lack of Funding and Development of New and Innovative Antifungal
Drug Classes
MARKET REVENUE ANALYSIS
NORTH AMERICA: MARKET REVENUE ANALYSIS
TABLE 37 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 11 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
NORTH AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 38 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 12 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
NORTH AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
FIGURE 13 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
UNITED STATES: MARKET REVENUE ANALYSIS
TABLE 39 UNITED STATES MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 40 UNITED STATES MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
CANADA: MARKET REVENUE ANALYSIS
TABLE 41 CANADA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 42 CANADA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
NORTH AMERICA: MARKET SHARE ANALYSIS
TABLE 43 NORTH AMERICA MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
CHAPTER 8 EUROPEAN MARKET FOR ANTIFUNGAL DRUGS
REGULATORY AND LEGISATIVE REQUIREMENTS: EUROPE
OVER-THE-COUNTER (OTC) ANTIFUNGAL DRUG PRODUCTS
THE RUSSIAN FEDERATION
MARKET DYNAMICS
MARKET DRIVERS
Changing Epidemiology of Invasive Fungal Diseases in Europe
Growing Aging Population in Europe
Increased Immunocompromised Population in Europe
Europe has Increasing Prevalence of Fungal Resistance
MARKET RESTRAINTS
Austerity Measures have been Introduced Throughout Europe
Growth and Development of the Generic Antifungal Drugs Market
Increased Competitive Product Pricing and Mandatory Tendering
Regarded as a Major Market Restraint
Major Challenges to the Development of New Antifungal Drugs
MARKET REVENUE ANALYSIS
EUROPE: MARKET REVENUE ANALYSIS
TABLE 44 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 14 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 212-2021 ($ MILLIONS)
EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 45 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 15 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, 2015 ($ MILLIONS)
EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
FIGURE 16 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
FRANCE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 46 FRANCE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 47 FRANCE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
GERMANY: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 48 GERMANY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 49 GERMANY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
ITALY: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 50 ITALY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 51 ITALY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
SPAIN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 52 SPAIN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 53 SPAIN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
UNITED KINGDOM: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 54 UNITED KINGDOM MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 55 UNITED KINGDOM MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
REST OF EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 56 REST OF EUROPE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 57 REST OF EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
EUROPE: MARKET SHARE ANALYSIS
TABLE 58 EUROPE MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS, 2015
CHAPTER 9 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS
JAPAN
REGULATORY AND LEGISLATIVE REQUIREMENTS
MARKETING AUTHORIZATION SYSTEM
Pharmaceutical Reimbursement Approval Process in Japan
FIGURE 17 JAPAN DRUG FUNDING/REIMBURSEMENT APPROVAL
PROCESS
CHINA
OVERVIEW OF THE HEALTHCARE SYSTEM
FIGURE 18 THE CHINESE HEALTHCARE SYSTEM
Healthcare Reforms
The New Rural Co-operative Medical Care System (NRCMCS)
The Urban Residents Healthcare Insurance Scheme
Healthcare Institutions
TABLE 59 NUMBER OF HEALTHCARE INSTITUTIONS ACCORDING TO OWNERSHIP IN CHINA, 2010
HOSPITAL RESOURCES
TABLE 60 TOTAL NUMBER OF HOSPITALS BY RANKING CHINA, 2010
Pharmaceutical Regulatory and Legislative Developments: China
INDIA
OVERVIEW OF THE HEALTHCARE SYSTEM
National Level
State Level
Regional Level
District Level
Sub-Divisional/Taluka Level
Community Level
Primary Health Center (PHC) level
Sub Health Center (SHC) level
TABLE 61 OVERVIEW OF HEALTHCARE IN INDIA
Hospital Resources
Population Statistics
Pharmaceutical Regulatory and Legislative Developments: India
SOUTH KOREA
REGULATORY AND LEGISLATIVE REQUIREMENTS
Pharmaceutical Regulatory and Legislative Developments: South Korea
Pharmaceutical Reimbursement: South Korea
MARKET DYNAMICS
MARKET DRIVERS
Increasing Resistance of Fungi to Antifungal Drugs
Increased Popularity of Traditional Medicines and Alternative
Treatments to Control Fungus
Growth and Development of Generic Drugs Market in Japan
Westernized Lifestyle Increases Incidence of IFIs in the Asia-Pacific
Region
Growth in the Indian Market
MARKET RESTRAINTS
China
India
Japan
Banning of Oral Formulations of Ketoconazole
MARKET REVENUE ANALYSIS
ASIA-PACIFIC: MARKET REVENUE ANALYSIS
TABLE 62 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 19 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 63 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 20 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
FIGURE 21 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
CHINA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 64 CHINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 65 CHINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
INDIA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 66 INDIA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 67 INDIA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
JAPAN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 68 JAPAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 69 JAPAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
SOUTH KOREA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
TABLE 70 SOUTH KOREA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 71 SOUTH KOREA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TAIWAN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 72 TAIWAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 73 TAIWAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
OTHER ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 74 OTHER ASIA-PACIFIC MARKETS FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 75 OTHER ASIA-PACIFIC MARKETS FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
ASIA-PACIFIC: MARKET SHARE ANALYSIS
TABLE 76 ASIA-PACIFIC MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
CHAPTER 10 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS
BRAZIL
BACKGROUND
REGULATORY AND LEGISLATIVE REQUIREMENTS
MARKET ENTRY AND REIMBURSEMENT OF PHARMACEUTICALS: BRAZIL
ARGENTINA
BACKGROUND
Government-funded Public Health Sector
Social Health Insurance Sector
Private Sector
Regulatory and Legislative Requirements
FIGURE 22 ARGENTINA: REGULATORY DRUG APPROVAL PROCESS
MEXICO
LEGISLATION AND REGULATIONS GOVERNING MEDICAL DEVICES IN MEXICO
Health Insurance Structure Mexico
MARKET DYNAMICS
MARKET DRIVERS
Growth and Development of the Pharmaceutical Market in Central and Latin America
Government Support to Boost Brazil Healthcare Sector
Increased Burden of Fungal Infections in Central and Latin America
Introduction of Tax Funded Universal Health Coverage throughout Latin
America
MARKET RESTRAINTS
Challenges Associated with Local Business Practices and Cultural
Conditions in Brazil
Issues Associated with Lack of Public Funding, a Weak Healthcare
Infrastructure, and a Lack of Affordability in Latin America
Pricing Issues
MARKET REVENUE ANALYSIS
LATIN AMERICA: MARKET REVENUE ANALYSIS
TABLE 77 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 23 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
LATIN AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 78 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 24 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
LATIN AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
FIGURE 25 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
ARGENTINA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 79 ARGENTINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 80 ARGENTINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
BRAZIL: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 81 BRAZIL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 82 BRAZIL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
CHILE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 83 CHILE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 84 CHILE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MEXICO: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 85 MEXICO MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 86 MEXICO MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
REST OF LATIN AMERICA (ROLA): MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 87 REST OF LATIN AMERICA (ROLA) MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 88 REST OF LATIN AMERICA (ROLA) MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
LATIN AMERICA: MARKET SHARE ANALYSIS
TABLE 89 LATIN AMERICA: MARKET SHARE ANALYSIS ANTIFUNGAL
DRUGS BY COMPANY, 2015
CHAPTER 11 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS
INTRODUCTION
SOUTH AFRICA
REGIONAL REGULATIONS, LEGISLATION AND REIMBURSEMENT: MIDDLE
EAST/AFRICA
MEDICAL DEVICE REGULATORY REQUIREMENTS: SOUTH AFRICA
HEALTH INSURANCE STRUCTURE: SOUTH AFRICA
REIMBURSEMENT OF PHARMACEUTICALS: SOUTH AFRICA
SAUDI ARABIA
THE PUBLIC HEALTHCARE SYSTEM
PRIMARY HEALTHCARE SERVICES
SECONDARY AND TERTIARY HEALTHCARE SERVICES
FIGURE 26 CURRENT STRUCTURE OF THE HEALTHCARE SECTORS IN SAUDI ARABIA 2012
FIGURE 27 NUMBER OF HOSPITALS IN SAUDI, BY TYPE, 2012
THE PRIVATE HEALTHCARE SECTOR
PHARMACEUTICAL REGULATORY REQUIREMENTS
HEALTH INSURANCE STRUCTURE
MARKET DYNAMICS
MARKET DRIVERS
Growth of Fungal Infections in Countries Affected by AIDS
The Global HIV/AIDS Epidemic
Fungal Toxins are Poisoning Africa: The Invisible Epidemic
Substantial Financial Support for Healthcare in Saudi Arabia
South Africa's Political Stability and Improved Economic Outlook
Helps Support Growth in the Healthcare Market
MARKET RESTRAINTS
Limited Infrastructure Capacity
Inherent Political and Economic Issues Constrain the Provision of Healthcare in Africa
Poor Distribution Structure and Networks in Africa
MARKET REVENUE ANALYSIS
MIDDLE/EAST/AFRICA: MARKET REVENUE ANALYSIS
TABLE 90 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 28 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
TABLE 91 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
FIGURE 29 MIDDLE EAST/AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
FIGURE 30 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL REGION, 2015 ($ MILLIONS)
MIDDLE EAST: MARKET REVENUE ANALYSIS
TABLE 92 MIDDLE EAST MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 93 MIDDLE EAST MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
AFRICA: MARKET REVENUE ANALYSIS
TABLE 94 AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
TABLE 95 AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
MARKET SHARE ANALYSIS
MIDDLE EAST/AFRICA: MARKET SHARE ANALYSIS
TABLE 96 MIDDLE EAST/AFRICA MARKET SHARE FOR ANTIFUNGAL DRUGS, BY COMPANY, 2015 ($ MILLIONS/%)
CHAPTER 12 COMPANY PROFILES
MANUFACTURERS OF PRESCRIPTION PHARMACEUTICALS
ANACOR PHARMACEUTICALS, INC.
ASTELLAS PHARMA INC.
BAYER HEALTHCARE
DR. REDDY'S LABORATORIES LTD.
ENZON PHARMACEUTICALS, INC.
FERRER INTERNACIONAL S.A.
GALDERMA PHARMA S.A. GALDERMA S.A.
GILEAD SCIENCES, INC.
GLENMARK PHARMACEUTICALS LIMITED
JANSSEN PHARMACEUTICALS INC. (JOHNSON AND JOHNSON)
MERCK
TABLE 97 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (MERCK) ($ MILLIONS)
MERZ PHARMA GMBH & CO. KGAA
MYLAN PHARMACEUTICALS INC. (MP LABORATORIES (MAURITIUS) LTD.)
NOVARTIS HOLDING AG
PFIZER INC.
TABLE 98 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (PFIZER) ($ MILLIONS)
SANOFI
SIGMA-TAU PHARMACEUTICALS, INC.
TARO PHARMACEUTICAL INDUSTRIES LTD.
TEVA PHARMACEUTICALS INDUSTRIES LTD.
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
FIGURE 31 PROGRESSION OF SALES OF JUBLIA ($ MILLIONS)
OTC ANTIFUNGAL MANUFACTURERS
PHARMACEUTICAL OTC MARKET
ALVA-AMCO PHARMACAL COS. INC.
TABLE 99 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
BLAINE LABS
DARTMOUTH PHARMACEUTICALS
KRAMER CONSUMER HEALTHCARE
MCNEIL CONSUMER HEALTHCARE
MOBERG PHARMA AB
PEDINOL, (A DIVISION OF VALEANT PHARMACEUTICALS)
PERRIGO COMPANY PLC
STIEFEL LABORATORIES, INC.
TARMAC PRODUCTS INC. (AXARA PHARMACEUTICAL)
ALTERNATIVE OTC MANUFACTURERS
TABLE 100 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGAL PRODUCTS
MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES
CRYSTAL STAR HERBAL NUTRITION
ENZYMEDICA
FOREST HERBS RESEARCH LTD.
GARDEN OF LIFE
KING BIO
LIFE EXTENSION NUTRITION CENTER
MICHAEL'S NATUROPATHIC PROGRAMS
NATURE'S PLUS
NOW FOODS
NUTRITION NOW
PROSYMBIOTICS
PURE ESSENCE LABORATORIES
RAINBOW LIGHT
RENEW LIFE
SOLARAY
VITANICA
CHAPTER 13 APPENDIXES
TABLE 101 COMPANY ADDRESSES AND CONTACT DETAILS
CHAPTER 14 GOVERNMENT REGULATORY AGENCIES AND
PROFESSIONAL ASSOCIATIONS
GOVERNMENT REGULATIONS
FOOD AND DRUG ADMINISTRATION (FDA)
TABLE 102 SELECTED ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 2005-2016
ENVIRONMENTAL PROTECTION AGENCY (EPA)
UNITED STATES DEPARTMENT OF AGRICULTURE (USDA)
FOOD AND AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS
PROFESSIONAL ASSOCIATIONS
MEDICAL AND VETERINARY ASSOCIATIONS
AGRICULTURAL ASSOCIATIONS
OTHER ENVIRONMENTAL ASSOCIATIONS
CHAPTER 15 COMMONLY USED ACRONYMS USED IN THIS REPORT

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report